# A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients

> **NCT00911859** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 118 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Siltuximab11 mg/kg
- **DRUG:** Siltuximab 8.3 mg/kg or 11 mg/kg
- **DRUG:** Velcade (bortezomib)
- **DRUG:** Velcade (bortezomib)
- **DRUG:** Melphalan
- **DRUG:** Melphalan
- **DRUG:** Prednisone
- **DRUG:** Prednisone
- **DRUG:** Velcade (bortezomib)
- **DRUG:** Melphalan
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT00911859
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2014-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00911859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00911859, "A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00911859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*